Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 7/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620795 | 0.73 | MAOA (0.55) | ALDH1A1 | |
| SCHEMBL26620818 | 0.71 | TSHR (0.45) | TSHRKDM4EALDH1A1SSTR3 | |
| SCHEMBL24316207 | 0.71 | TRPV3 (0.41) | TSHRTRPV3KDM4EALDH1A1SSTR3 | |
| SCHEMBL1764060 | 0.70 | — | — | |
| SCHEMBL26620801 | 0.70 | KDM1A (0.49) | KDM4EALDH1A1SSTR3 | |
| SCHEMBL26620820 | 0.70 | TRPV3 (0.45) | TRPV3SSTR3 | |
| SCHEMBL26641275 | 0.70 | TRPV3 (0.42) | TRPV3 | |
| SCHEMBL20096129 | 0.69 | KDM1A (0.50) | KDM4EALDH1A1SSTR3 | |
| SCHEMBL26620794 | 0.69 | KDM1A (0.50) | KDM4EALDH1A1SSTR3 | |
| SCHEMBL24316230 | 0.68 | SSTR3 (0.58) | TSHRKDM4EALDH1A1SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | TSHR 3937/4885TRPV3 4679/4885KDM4E 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.